-SEC Filing
AstraZeneca’s COVID-19 Therapy Hits Goal In Phase 3 Trial
AstraZeneca Plc (NASDAQ: AZN) released
Related Posts
Lack Of E-Commerce Visibility Leads To Squarespace Downgrade, Analyst Says
KeyBanc analyst Josh Beck downgraded Squarespace, Inc (NYSE:SQSP) to Sector Weight from Overweight without a price target. The re-rating reflected a more…
UPDATE: Meten EdtechX May Gross Billings Up ~248% Year Over Year
Meten EdtechX Education Group Ltd. (NASDAQ:METX) ("Meten EdtechX" or the "Company"), one of the leading omnichannel English language training ("ELT") service providers in China, today
Wells Fargo Maintains Underweight on BP, Lowers Price Target to $29
Wells Fargo analyst Roger Read maintains BP (NYSE:BP) with a Underweight and lowers the price target from $31 to $29.